AMX-525
- Generic Name
- AMX-525
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor MalignanciesEGFR Positive Solid TumorsEGFR
- Interventions
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT06960395
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇦🇺Wollongong Hospital, Wollongong, New South Wales, Australia
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath